Navigation Links
NeuroVive Pharmaceutical AB Publishes 2016 Annual Report
Date:3/23/2017

LUND, Sweden, Mar 23, 2017 /PRNewswire/ --

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for 2016 is now available on the company's website www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company's strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.

NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:

Cecilia Hofvander
NeuroVive
Tel: +46-(0)46-275-62-21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village
SE-223 81 Lund, Sweden
Tel: +46-(0)46-275-62-20 (switchboard)
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:35 a.m. CET on March 23, 2017.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-publishes-2016-annual-report,c2221355

The following files are available for download:

http://mb.cision.com/Main/6574/2221355/646778.pdf

NeuroVive Pharmaceutical AB publishes 2016 Annual report

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurovive-pharmaceutical-ab-publishes-2016-annual-report-300428340.html


'/>"/>
SOURCE NeuroVive Pharmaceutical
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
2. NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma
3. NeuroVive Redirects Research Resources From Asian Subsidiary to Parent
4. NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader
5. NeuroVive Signs Collaboration Agreement With Karolinska Institutet
6. Update - Ampio Pharmaceuticals Provides Corporate Update
7. China Pharmaceutical Packaging Industry Report, 2016-2021
8. Global Pharmaceutical Packaging Market to Reach $129.8 Billion by 2025 - Rising Demand for Primary Pharmaceutical Packaging in Emerging Markets - Research and Markets
9. Imprimis Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering
10. InDex Pharmaceuticals Concludes Well Attended Investigators Meeting for the Phase IIb Study Conduct
11. Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):